sponsored
PatientsVille.com Logo

PatientsVille

Tamiflu Medical Research Studies

Up-to-date List of Tamiflu Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Tamiflu Medical Research Studies

Rank Status Study
1 Recruiting Panama and El Salvador Children's Oseltamivir Study
Conditions: Influenza;   Human Influenza
Interventions: Drug: Oseltamivir phosphate suspension;   Drug: Placebo
Outcome Measures: Length of hospitalization;   Time to resolution of increased work of breathing;   Time to resolution of hypoxia;   Incidence of new onset respiratory failure 24 hours or more after first dose of study medication;   Incidence of admission to intensive care unit 24 hours or more after first dose of study medication;   Incidence of death 24 hours or more after first dose of study medication;   Time to non-detectable influenza virus by viral culture and non-detectable influenza viral RNA by RT-PCR;   Proportion of children with oseltamivir resistant virus detected during or after oseltamivir phosphate treatment who had oseltamivir susceptible virus infection at enrollment;   Proportion of participants experiencing adverse events (including severe and non-severe)
2 Recruiting A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
Condition: Influenza, Human
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo;   Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo;   Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Outcome Measures: Time to clinical response in subjects with confirmed influenza treated with 300 mg or 600 mg IV zanamivir compared with 75 mg oral oseltamivir;   Changes in the Katz Index of Independence in Activities of Daily Living (ADL) score and time to return to pre-morbid level of activity;   Mortality rate at Day 14 and Day 28;   Disease progression and complications of influenza;   Summary of ventilation status;   Duration of hospitalization and ICU (intense care unit) stay;   Time to improvement of vital signs;   Time to reduction in viral load and percentage of patients with undetectable viral RNA obtained from upper and lower respiratory samples;   Changes in viral susceptibility;   Pharmacokinetics of IV Zanamivir as measured by minimum or maximum serum concentration;   Safety and tolerability as measured by the incidence of adverse events and laboratory abnormalities;   ECG(electrocardiogram) data
3 Recruiting A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
Condition: Influenza
Intervention: Drug: oseltamivir
Outcome Measures: Safety (incidence of adverse events);   Tissue rejection or graft versus host disease in transplant patients;   Development of viral resistance to Tamiflu;   Time to alleviation of all clinical influenza symptoms;   Proportion of viral shedding;   Viral load;   Pharmacokinetics: Area under the concentration-time curve (AUC);   Development of secondary illnesses
4 Recruiting Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
Condition: Influenza
Interventions: Drug: Amantadine, Ribavirin, Oseltamivir;   Drug: Oseltamivir
Outcome Measure: Evaluate the reproducibility of virologic samples, comparison between culture and PCR, and the impact of missing data between randomized groups.
5 Recruiting A Pharmacokinetic/Pharmacodynamic Study of Tamiflu (Oseltamivir) in Immunocompromised Children With Confirmed Influenza Infection
Condition: Influenza
Intervention: Drug: oseltamivir [Tamiflu]
Outcome Measures: Pharmacokinetics: Area under the concentration-time curve (AUC);   Pharmacodynamics: Time to cessation of viral shedding;   Time to resolution of influenza symptoms;   Safety: Incidence of adverse events;   Safety: Incidence of influenza associated complications;   Frequency of viral resistance
6 Recruiting A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia With High Platelet Desialylation Level
Condition: Focus of Study
Interventions: Drug: Oseltamivir;   Drug: Dexamethasone
Outcome Measure: Evaluation of platelet response
7 Recruiting Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
Condition: Influenza, Human
Interventions: Drug: Oseltamivir;   Drug: Oseltamivir Placebo
Outcome Measures: Primary endpoint will be determined after analysis of the pilot study, which will include the first 50 participants enrolled in the study;   Time to alleviation of influenza clinical symptoms;   Time to absence of fever;   Time to resumption of normal activity;   Number of premature study treatment discontinuations;   Proportion of participants who develop bronchitis, pneumonia, or other complications of influenza;   Proportion of participants who require hospitalization;   28-day mortality;   Duration of viral shedding;   Change in viral shedding as a function of time;   Area under the curve (AUC) of viral shedding;   Frequency of emergence of antiviral resistance
8 Unknown  Characterisation of the Human Carboxylesterase 1 (CES1) Mutations in Thailand
Condition: Metabolic Disease
Intervention: Drug: Oseltamivir
Outcome Measures: Tmax;   Conversion of oseltamivir phosphate to oseltamivir carboxylate
9 Recruiting Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Condition: Influenza
Interventions: Drug: Nitazoxanide;   Drug: Oseltamivir
Outcome Measures: Time to resolution of all clinical symptoms of influenza as reported by the subjects;   Time to resolution of each individual symptom of influenza
10 Unknown  Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study
Condition: Influenza
Interventions: Drug: oseltamivir;   Drug: oseltamivir and chinese medicinal herbs
Outcome Measures: Efficacy rate in 5 days (defined as failure: SaO2<90% at room air or temperature elevated continuously);   Time to resolution of fever(defined as the period from start of study-drug to relief of fever);   Time to resolution of respiratory symptoms(defined as the period from start of study-drug to relief of symptoms);   Virus shedding time;   Infiltration resolution of chest radiology;   SaO2 and PaO2/FiO2(arterial blood gas)
11 Recruiting Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza
Condition: Influenza
Interventions: Drug: Ergoferon;   Drug: Oseltamivir(Tamiflu)
Outcome Measures: Proportion of patients whose body temperature normalized (no more than 37.0ºС);   Proportion of patients whose influenza clinical manifestations were arrested
12 Recruiting Treatment of Severe Influenza A Infection
Condition: Influenza, Human
Interventions: Drug: Celecoxib;   Drug: Oseltamivir;   Drug: Placebo
Outcome Measures: Mortality rate;   Viral load;   Cytokine;   Intensive care stay;   Ventilatory support period;   Systemic adverse events;   Hospitalization
13 Unknown  Clinical Evaluation of QFlu Combo Test
Conditions: Cough;   Myalgia;   Nasal Obstruction;   Sore Throat;   Headache;   Fatigue;   Fever
Intervention:
Outcome Measures: Sensitivity and specificity for drug resistance detection;   Sensitivity and Specificity of the Test for Influenza Diagnosis
14 Unknown  Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant
Conditions: Respiratory Tract Infections;   Bronchiolitis Obliterans;   Cryptogenic Organizing Pneumonia;   Lung Diseases, Interstitial
Interventions: Drug: Prednisone;   Drug: Azithromycin;   Drug: Montelukast;   Drug: Symbicort
Outcome Measures: Cumulative incidence of new chronic lung disease;   Prevalence of non-infectious pulmonary complications;   Long-term functional impairment as defined by need for supplemental oxygen;   Patient-perceived long-term functional impairment;   Time to clearance of viral infection;   Incidence of progression to respiratory failure;   Incidence of bacterial or fungal superinfection;   Incidence of various other infectious complications;   Overall survival from date of viral respiratory tract infection;   Overall survival from date of transplant to end of study follow-up;   Overall survival at 1 year post-transplant;   Cumulative incidence of death attributable to transplant associated lung disease;   Cumulative incidence of death from other causes

These studies may lead to new treatments and are adding insight into Tamiflu etiology and treatment.

A major focus of Tamiflu research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Tamiflu